Cardiometabolic Risk Assessment with Standard Labs
A page-by-page look at the report your patient receives: what each score measures, where it comes from, and how to use it in a visit. The patient sees the same pages with plain-language explanations; this guide adds the methods and evidence behind them.
What goes into the report
- Quest Diagnostics fasting panel: standard lipid panel, ApoB (Cardio IQ), lipoprotein(a), hs-CRP, fasting glucose and insulin, hemoglobin A1C, and a basic metabolic panel including eGFR. The liver screening also requires AST, ALT, and a platelet count.
- Pre-assessment survey: anthropometrics and blood pressure, medications, smoking, family history, prior cardiovascular testing and events, familial hypercholesterolemia features, and the conditions that count as risk-enhancing factors.
- Guideline frameworks: AHA PREVENT equations, the risk-enhancing factors in the 2026 AHA/ACC/NLA cholesterol guideline, harmonized metabolic syndrome criteria, the MetS severity score from MetS Calc, AHA CKM staging, and FIB-4 thresholds from AGA/AASLD guidance.
HOMA-IR requires fasting glucose and insulin, so the draw must be fasting.
Reading the scales
Every scale runs green (lower risk) to red (higher risk). Category labels follow the source guideline or model, so they differ by domain:
| Domain | Categories |
|---|---|
| HOMA-IR (0.5–4.5) | Optimal, Near Optimal, Intermediate, High, Very High |
| MetS severity percentile; PREVENT 10- and 30-year | Low, Borderline, Intermediate, High |
| 5-year T2D risk; overall CV risk | Low, Moderate, High, Very High |
| Hemoglobin A1C | Normal, Pre-Diabetes, Diabetes |
| FIB-4 | Low (<1.3), Indeterminate, High (>2.67) |
| CKM stage | Stage 0–4 |
A white circle marks the current value; an X marks a category result. In follow-up reports a gray box marks the baseline value. In the metabolic syndrome table, yellow cells meet a criterion and red cells flag hs-CRP or ApoB above the high-risk cutoff. On the CKM page, each factor is marked Present, —, or Not assessed.
Methods at a glance
Each score in the report comes from a published method or guideline. The one exception is how the overall cardiovascular risk category combines PREVENT with risk-enhancing factors, which is our own method.
| Measure | How it is derived | Refs |
|---|---|---|
| HOMA-IR | Homeostatic model assessment of insulin resistance: fasting insulin (µIU/mL) × fasting glucose (mg/dL) ÷ 405. The scale’s hash marks sit at the 5th, 25th, 50th, 75th, and 95th percentiles for the patient’s sex and ethnicity, adjusted for whether fasting glucose and A1C agree. | Matthews DR, et al. Diabetologia 1985 |
| 5-year T2D risk | Sex-specific probability of incident type 2 diabetes from a Precision Health Reports model developed by our Chief Medical Officer, integrating A1C, fasting glucose, and HOMA-IR. Displayed against A1C with curves for the 5th and 95th percentiles of HOMA-IR. | Internal model |
| MetS severity score | Sex- and race/ethnicity-specific continuous score from a confirmatory factor analysis of the five MetS components in NHANES adults, calculated with MetS Calc (metscalc.org). It behaves like a z-score and is reported as a percentile of U.S. adults. Higher scores predict incident diabetes, coronary heart disease, CVD, and ischemic stroke. | 9–16 |
| Metabolic syndrome | Harmonized criteria: waist above the sex- and ethnicity-specific cutoff, BP ≥130/85, fasting glucose ≥100, triglycerides ≥150, HDL-C <40 (men) or <50 (women), or drug treatment for that factor. Three or more criteria means metabolic syndrome. | 7, 8 |
| PREVENT risk | AHA PREVENT equations: 10-year and 30-year risk on the cardiovascular page, and 10-year total CVD risk for the CKM Stage 3 threshold, from the patient’s labs (including eGFR) and survey data. | Khan SS, et al. Circulation 2024 |
| Overall CV risk | Combines calculated PREVENT risk with every risk-enhancing factor in the 2026 AHA/ACC/NLA cholesterol guideline that applies to the patient, from labs, imaging history, and survey answers. | — |
| Lipoprotein goals | For the patient’s overall risk category, each LDL-C, non-HDL-C, and ApoB threshold goal is the lower of the guideline’s recommended percent reduction from baseline or its absolute target. ApoB is emphasized because particle number tracks risk reduction more closely than cholesterol content. | 17–22, 29, 30 |
| hs-CRP | High-sensitivity C-reactive protein. Values above 3.0 mg/L are flagged as a high-risk metabolic syndrome factor, consistent with AHA/CDC risk categories. | Pearson TA, et al. Circulation 2003 |
| FIB-4 | (Age × AST) ÷ (platelets × √ALT). <1.3 low and >2.67 high risk of advanced fibrosis, with a higher low-risk cutoff at age 65 and older. Not validated below age 35, so the page is omitted for younger patients. | Sterling 2006; AGA 2021; AASLD 2023 |
| CKM stage | AHA CKM staging, 0 to 4, set by the highest stage with at least one factor present, using report labs, PREVENT, and survey history. Kidney risk uses the KDIGO eGFR and albuminuria categories and reads “Not assessed” unless the optional urine albumin test was ordered. | Ndumele 2023 |
Page by page
Click any sample page to see it larger. The sample is an initial report. The liver page is included by default; it is omitted if the ordering organization removes it or the patient is younger than 35, and later pages shift up by one.
Cover
Patient, report date, and ordering provider.
- Identifies the patient and the ordering clinician or organization
- Frames the report as decision support for shared decision-making, not a substitute for it
Click anywhere to close
Letter from the Chief Medical Officer
Sets the patient’s mental model before the numbers.
- Presents insulin resistance as the common driver of metabolic syndrome, type 2 diabetes, and ASCVD
- Explains that personal risk goes beyond major risk factors and population equations, and includes more than 30 guideline risk-enhancing factors
- Emphasizes that risk is modifiable and that response should be tracked with retesting
Click anywhere to close
Cardiometabolic Risk Summary
Five risk domains on one page for quick triage.
- HOMA-IR, the report’s anchor for insulin resistance
- MetS severity percentile, with category boundaries at the 25th, 50th, and 75th percentiles
- 5-year type 2 diabetes risk, with category boundaries at 5%, 10%, and 20%
- Overall cardiovascular risk category, from Low to Very High, after risk-enhancing factors are applied
- CKM stage, 0 to 4, detailed on page 8
Click anywhere to close
Metabolic Risk Details
Insulin resistance, metabolic syndrome criteria, and severity.
- HOMA-IR from fasting glucose and insulin, plotted against percentile hash marks specific to the patient’s sex and ethnicity.
- The five metabolic syndrome criteria with sex- and ethnicity-specific waist cutoffs. Criteria met are shaded yellow, and treatment for a factor counts as meeting it.
- Two additional high-risk factors shaded red when exceeded: hs-CRP >3.0 mg/L and ApoB >110 mg/dL
- MetS severity score (MetS Calc), reported as a sex- and race/ethnicity-specific percentile of U.S. adults. Unlike the yes/no diagnosis, it captures severity below the diagnostic threshold and changes with treatment.
Click anywhere to close
Diabetes Risk Details
Current glycemic status and forward-looking diabetes risk.
- Hemoglobin A1C on a Normal, Pre-Diabetes, and Diabetes scale, with breakpoints at 5.7% and 6.5%
- HOMA-IR with its category scale
- 5-year probability of incident type 2 diabetes plotted against A1C, with curves for the 5th and 95th percentiles of HOMA-IR
- Risk bands are labeled by intervention intensity, from minimal (low risk) to maximum (very high risk), so the chart doubles as a counseling tool
Click anywhere to close
Liver Fibrosis Details (FIB-4)
Noninvasive screening for advanced fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD).
- Shows the inputs (age, AST, ALT, platelets) and the FIB-4 score on a Low, Indeterminate, and High scale with cutoffs at 1.3 and 2.67; the low-risk cutoff is raised for patients 65 and older
- Plain-language interpretation and a recommended next step for the patient to discuss with you
- Notes that advanced fibrosis is an emerging cardiovascular risk enhancer. The FIB-4 result itself does not feed the cardiovascular risk calculation, but a reported MASLD diagnosis is counted as a risk-enhancing factor.
- Included by default; omitted when the ordering organization removes it or the patient is younger than 35, where FIB-4 is not validated
Click anywhere to close
Cardiovascular Risk Details
Calculated risk, risk-enhancing factors, overall category, and lipoprotein goals.
- PREVENT 10-year risk with categories at 3%, 5%, and 10%, and 30-year risk with categories at 10%, 19%, and 24%. The report notes that lipid-lowering therapy is recommended at a 10-year risk of 5% or more, or a 30-year risk of 10% or more.
- Clinical risk-enhancing factors present for this patient, drawn from labs (such as LDL-C, non-HDL-C, ApoB, Lp(a), and hs-CRP), imaging history (such as a CAC score), and survey conditions (including family history, sleep apnea, and sex-specific factors)
- Overall cardiovascular risk category, from Low to Very High, combining PREVENT with all applicable risk-enhancing factors in the 2026 AHA/ACC/NLA guideline
- Personalized LDL-C, non-HDL-C, and ApoB threshold goals for that category, shown next to baseline and current values. Each goal is the lower of the recommended percent reduction from baseline or the absolute target.
Click anywhere to close
Cardiovascular-Kidney-Metabolic (CKM) Stage
AHA CKM staging, with every factor shown so the stage is transparent.
- Stage scale 0–4 with the patient’s stage marked, then a factor table grouped by stage: threshold, patient value, and status (Present, —, or Not assessed)
- Stage 1: excess or dysfunctional adiposity (BMI ≥25 or waist above threshold) and prediabetes (fasting glucose ≥100 or A1C ≥5.7%)
- Stage 2: blood pressure ≥130/80 or treated, triglycerides ≥135 mg/dL or treated, diabetes, metabolic syndrome, and KDIGO moderate- or high-risk CKD. Self-reported familial hypercholesterolemia is listed as a major risk factor, though it is not a standard CKM criterion.
- Stage 3: subclinical atherosclerosis (CAC >99 or ≥75th percentile), diagnosed LVH, stage 3–4 CKD, KDIGO very-high-risk CKD, or PREVENT 10-year total CVD risk ≥20%
- Stage 4: clinical ASCVD (MI, stroke or TIA, angina, claudication, revascularization), heart failure, atrial fibrillation, or aortic aneurysm
- Footnotes explain where CKM thresholds are stricter than the metabolic syndrome criteria, and when BMI may overstate adiposity because waist circumference is normal
Click anywhere to close
Additional Topics for Discussion
Narrative talking points generated from the patient’s results and survey.
- Short explanations of findings that warrant discussion, such as severely elevated LDL-C or ApoB, high Lp(a), elevated hs-CRP, or whether noninvasive imaging may be a reasonable next step
- Links to patient education pages for each topic, and to the reference list
Click anywhere to close
Tracking Charts
Serial values against goals, designed for retesting.
- Metabolic risk tracking: the five MetS components, the severity score, and hs-CRP at each test
- Diabetes risk tracking: A1C, fasting glucose, HOMA-IR, and estimated 5-year risk
- Atherogenic lipoprotein tracking: LDL-C, non-HDL-C, and ApoB against each threshold goal
- A QR code on the divider page links the patient to a reference page for every topic in the report
Pre-Assessment Survey Responses
Every patient-reported input that feeds the calculations.
- Height, weight, waist, BMI, and blood pressure, which drive the MetS criteria, MetS severity score, PREVENT, and CKM stage
- Blood pressure and glucose history and treatment, smoking, and family history of diabetes and premature ASCVD
- Prior vascular testing (CAC, CTA, carotid ultrasound, ABI, angiography) and any events or procedures
- LDL-C history and familial hypercholesterolemia features, current lipid therapy, and conditions that count as risk-enhancing factors, including sex-specific factors
Click anywhere to close
Quest Diagnostics Lab Report
The complete Quest Diagnostics report, unaltered.
- Standard lipid panel (LDL-C by the Martin-Hopkins calculation)
- Cardio IQ ApoB and lipoprotein(a)
- hs-CRP, fasting glucose and insulin, and hemoglobin A1C
- Basic metabolic panel, including eGFR
Click anywhere to close
Follow-up reports
Follow-up reports keep the same structure and add the patient’s baseline beside each current value.
- On every scale, a gray box marks the baseline value and a white circle marks the current value
- Detail tables show baseline and current columns, colored by the same criteria
- Lipoprotein threshold goals stay anchored to the baseline values, so percent-reduction goals don’t drift as values improve
- Tracking charts add a point for each test. The report suggests reassessing every 3 to 6 months, depending on risk.
See it with your own patients
Ordering takes about 30 seconds, and we deliver the completed report in a few days. We’re happy to walk through a sample with you.
Sample pages have all personal details removed. Reference numbers match the list on our references page. Precision Health Reports supports, and does not replace, clinical judgment.